Immunotherapy drug becomes first therapy approved by FDA for rare skin cancer

The U.S. Food and Drug Administration has granted accelerated approval to the checkpoint inhibitor Bavencio (avelumab) for the treatment of patients with metastatic Merkel cell carcinoma.